Compositions comprising doses of NSAIDs less than 75 mg are provided. As shown herein, these compositions may be used for the treatment and prophylaxis of inflammatory conditions on the mucosa. In particular, acetyl salicylic acid at doses of less than 75 mg is shown to have therapeutic and prophylactic effect on the mucosa coupled without the adverse effects associated with NSAID administration.

The invention provides methods for producing soluble di-chain BoNT/A protein.

Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.

In general, the invention relates to pharmaceutical compositions comprising a thyrotropin-releasing hormone (TRH) analog, and methods of treating sleep apnea comprising administering a TRH analog.

In general, the invention relates to pharmaceutical compositions comprising a thyrotropin-releasing hormone (TRH) analog, and methods of treating sleep apnea comprising administering a TRH analog.

Provided here is a liquid formulation comprising recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) for inhalation by nebulization.

Disclosed are compounds of formula I ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.

It is a composition comprising young barley grass, used for promoting salivary IgA secretion, maintaining or improving oral immune function, or mucosal immune function, or preventing or alleviating upper airway infection.

The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.